Skip to main content
VivoSim Labs, INC. logo

VivoSim Labs, INC. — Investor Relations & Filings

Ticker · VIVS ISIN · US68620A2033 US Professional, scientific and technical activities
Open in API
Filings indexed 790 across all filing types
Latest filing 2024-11-14 Major Shareholding Noti…
Country US United States of America
Listing US VIVS

About VivoSim Labs, INC.

https://organovo.com/

VivoSim Labs, Inc. is a biotechnology services company that develops and utilizes bioprinted, three-dimensional (3D) human tissues designed to emulate human biology and disease. The company provides testing services for drugs and drug candidates, primarily for the pharmaceutical and biotechnology sectors. VivoSim Labs specializes in offering liver and intestinal toxicology insights through its proprietary New Approach Methodologies (NAMs), including its NAMkind™ 3D models. These non-animal testing platforms are used to generate human-relevant safety and toxicology data early in the drug discovery and development process, aiming to provide insights before animal studies or clinical trials.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2024
Major Shareholding Notification
2024-11-14 English
10-Q
Interim / Quarterly Report Q2 2025
2024-11-08 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a preliminary prospectus for an offering of common stock and warrants by Organovo Holdings, Inc. The text includes detailed information about the securities being offered, the offering process, risk factors, use of proceeds, and other disclosures typical of an S-1 filing. This type of document is used to register securities for public offering and is not an annual report, earnings release, or other financial report. It is a capital markets filing related to fundraising and issuance of new securities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high due to clear identification of the form and content.
2024-10-25 English
ARS
Annual Report
2024-10-07 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes details about the upcoming Annual Meeting of stockholders, including proposals to be voted on such as election of directors, ratification of auditors, executive compensation advisory vote, employee stock purchase plan approval, and amendment to the Certificate of Incorporation. The document is titled 'Definitive Additional Materials' related to the proxy statement and contains voting instructions and proposal summaries. This matches the definition of Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The document length is under 5,000 characters and it is not a full Annual Report or Management Report but a proxy solicitation document. Therefore, the correct classification is PSI with high confidence.
2024-10-07 English
DEF 14A
Proxy Solicitation & Information Statement
2024-10-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.